Yazar "Öztürk, Türkan" için listeleme
-
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
Gümüş, Mahmut; Bilici, Ahmet; Odabaş, Hatice; Öven Ustaalioğlu, Bala Başak; Kandemir, Nurten; Demirci, Umut; Cihan, Şener; Bayoğlu, İbrahim Vedat; Öztürk, Türkan; Türkmen, Esma; Urakçı, Zürat; Şeker, Mehmet Metin; Günaydın, Yusuf; Selçukbiricik, Fatih; Turan, Nedim; Sevinç, Alper (Springer, 2017)Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ... -
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors
Bilici, Ahmet; Gümüş, Mahmut; Odabaş, Hatice; Kandemir, Nurten; Demirci, Umut; Cihan, Şener; Bayoğlu, İbrahim Vedat; Öven Ustaalıoğlu, Bala Başak; Öztürk, Türkan; Türkmen, Esma; Urakçı, Zuhat; Şeker, Mehmet Metin; Günaydın, Yusuf; Selçukbiricik, Fatih; Turan, Nedim; Sevinç, Alper (American Society of Clinical Oncology, 2016)... -
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
Bilici, Ahmet; Öztürk, Türkan; Türkmen, Esma; Odabaş, Hatice; Cihan, Şener; Selçukbiricik, Fatih; Erdoğan, Bülent; Urakçı, Zuhat; Kandemir, Nurten; Bayoğu, İbrahim Vedat; Demirci, Umut; Ocak Duran, Ayşe; Şendur, Mehmet Ali; Yavuzer, Dilek; Harputluoğlu, Hakan; Kavgacı, Halil; Gümüş, Mahmut (Springer, 2015)Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...